Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Debt to Equity (2020)

Vistagen Therapeutics' Debt to Equity history spans 3 years, with the latest figure at $0.02 for Q3 2020.

  • For Q3 2020, Debt to Equity changed N/A year-over-year to $0.02; the TTM value through Sep 2020 reached $0.02, changed N/A, while the annual FY2016 figure was -$0.01, N/A changed from the prior year.
  • Debt to Equity for Q3 2020 was $0.02 at Vistagen Therapeutics, up from -$0.02 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.02 in Q3 2020 and bottomed at -$0.02 in Q2 2020.